Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Diseases 1

Interventions

Bevacizumab 21Paclitaxel 19Carboplatin 15pembrolizumab 14Specimen Handling 14liposomal doxorubicin 12Magnetic Resonance Spectroscopy 12Cyclophosphamide 11olaparib 10Gemcitabine 10fludarabine 9Topotecan 8Biopsy 8Fulvestrant 7niraparib 6Nivolumab 6palbociclib 5Taxes 5Immunoglobulin G 5Doxorubicin 5Disulfides 5aldesleukin 4trastuzumab deruxtecan 3mirvetuximab soravtansine 3binimetinib 3Oxaliplatin 3Cisplatin 3AZD5305 31-dodecylpyridoxal 3ulixertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Imlunestrant × 30 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡